The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - SERVIER
Research Funding - Celgene
TGF-β and PD-L1 inhibition combined with definitive chemoradiotherapy in esophageal squamous cell carcinoma: A phase II clinical trial (NCT04595149).
 
Linde Veen
No Relationships to Disclose
 
Maarten C.C.M. Hulshof
No Relationships to Disclose
 
Connie R. Jimenez
No Relationships to Disclose
 
Edwin P.J.G. Cuppen
No Relationships to Disclose
 
Laurens V. Beerepoot
No Relationships to Disclose
 
Geert-Jan Creemers
No Relationships to Disclose
 
W. Edward Fiets
No Relationships to Disclose
 
Paul M. Jeene
No Relationships to Disclose
 
Djoeri Lipman
No Relationships to Disclose
 
Nadia Haj Mohammad
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Lilly; MSD
 
Vera Oppedijk
No Relationships to Disclose
 
Marije Slingerland
No Relationships to Disclose
 
Walter L. Vervenne
No Relationships to Disclose
 
Maarten F. Bijlsma
No Relationships to Disclose
 
Hanneke W.M. Van Laarhoven
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly/ImClone; Nordic Group; Servier
Research Funding - Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Lilly (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Nordic Group (Inst); Philips Healthcare (Inst); Roche (Inst); Servier (Inst)
Travel, Accommodations, Expenses - AstraZeneca